Market Closed -
Nasdaq
04:00:00 2024-06-03 pm EDT
5-day change
1st Jan Change
1.81
USD
-0.55%
+4.02%
-66.57%
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome, everyone, to the ...
Transcript : GeoVax Labs, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14
GeoVax Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 14
CI
GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Mar. 28
CI
GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System
Mar. 06
CI
Transcript : GeoVax Labs, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Feb. 29
GeoVax Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 29
CI
GeoVax Labs Gets Two Patents from US Patent and Trademark Office
Feb. 13
MT
Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster
Feb. 06
CI
Transcript : GeoVax Labs, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02:30 PM
Jan. 08
Geovax Appoints Marc Pipas as Executive Medical Director, Oncology
Jan. 08
CI
GeoVax Labs, Inc. Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
Jan. 04
CI
GeoVax Labs Files for 21.1 Million Share Offering by Selling Shareholder
Jan. 02
MT
Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02
Nov. 14
CI
Transcript : GeoVax Labs, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Nov. 08
GeoVax Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 08
CI
GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
23-10-30
CI
GeoVax Labs Gets Notice of Allowance for US Patent Application Covering Marburg Vaccine
23-10-09
MT
GeoVax Labs' HIV Vaccine Patent Gets Notice of Allowance from US Patent and Trademark Office
23-10-05
MT
GeoVax Labs, Inc. Secures Multi-Product License for Probiogen's Age1.Cr.Pix(R) Suspension Cell Line to Bolster MVA-Based Vaccine Development
23-09-26
CI
Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
23-09-19
CI
GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
23-09-11
CI
GeoVax Labs Says it Received Allowance Notice for Malaria Vaccine Patent Application
23-08-28
MT
GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
23-08-10
CI
Transcript : GeoVax Labs, Inc., Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
GeoVax Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-09
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Companyâs portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
More about the company
Last Close Price
1.81
USD
Average target price
90
USD
Spread / Average Target
+4,872.37%
Consensus
1st Jan change
Capi.
-66.57% 4.58M +48.64% 56.65B -6.44% 39.44B +37.07% 39.03B +14.28% 26.75B -11.17% 26.86B -21.40% 19.03B +25.64% 12.26B +0.96% 12.28B +27.04% 12.04B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1